CRISPR/Cas9, the gene editing tool that enables highly-efficient and precise modifications to DNA, has been a disruptive force in scientific research and drug discovery. While CRISPR possesses significant ease-of-use advantages over former gene editing methods, it is an advanced tool requiring careful experimental design for optimal outcomes.
Ask Us About CRISPR »
Charles River acquired a license from the Broad Institute to work with CRISPR in May 2014. Charles River biologists employ CRISPR for target screening alone or alongside RNAi screening with our shRNA library (SilenceSelect®) and to create complex custom knock-in and knockout cell lines with applications throughout the drug discovery continuum:
Target discovery and validation: gRNA library screening, disease-relevant phenotypic screening
Hit discovery: Generate knock-in cell lines expressing your gene of interest to use in cell-based HTS assays
Hit-to-lead: Precision mutagenesis of tumor cell lines
Lead-to-candidate: ES cell modification for custom transgenic mouse models
Below are example project timelines:
CRISPR-Cas9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.